A Look At LivaNova (LIVN) Valuation After Recent Share Price Weakness

LivaNova Stock: Event Trigger and Initial Takeaways

LivaNova (LIVN) has drawn investor attention after recent share performance data showed a 1 day decline of about 1.3% and a roughly 8.8% drop over the past month.

See our latest analysis for LivaNova.

While the 30 day share price return of about 8.8% and the recent 1 day move have been weak, the 1 year total shareholder return of 56.31% and 3 year total shareholder return of 48.50% suggest earlier momentum has eased rather than reversed.

If you are weighing LivaNova against other opportunities in medical technology, it can be helpful to see how specialist healthcare names using AI are trading right now via 36 healthcare AI stocks

With LivaNova trading at US$62.40, alongside an indicated discount to analyst targets and intrinsic estimates, the key question for you is simple: is this a genuine value opportunity, or is the market already factoring in future growth?

Most Popular Narrative: 21.9% Undervalued

With LivaNova closing at $62.40 against a narrative fair value of $79.91, the current setup centers on how its core therapies could reshape earnings power.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Read the complete narrative.

Curious what kind of revenue mix, margin shift, and earnings profile would need to line up for that valuation gap to close? The full narrative spells out the revenue build, profit inflection, and valuation multiple that underpin this fair value call without assuming everything goes right.

Result: Fair Value of $79.91 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you should also keep an eye on rising healthcare cost pressures and any clinical or reimbursement setbacks that could limit pricing power or slow therapy adoption.

Find out about the key risks to this LivaNova narrative.

Next Steps

The setup here is optimistic but not one sided, so it makes sense to check the underlying data yourself and move quickly while sentiment is clear. To understand what others are already cheering, review the 4 key rewards

Looking for more investment ideas?

If LivaNova is on your radar, do not stop here. Broaden your watchlist with fresh ideas so you are not relying on a single opportunity.

• Target reliable cash generators by scanning for companies on the solid balance sheet and fundamentals stocks screener (39 results) that may better withstand shocks and funding stresses.
• Hunt for potential bargains by checking companies on the 59 high quality undervalued stocks that pair quality fundamentals with prices that appear out of step with their financials.
• Spot underfollowed opportunities early by reviewing the screener containing 25 high quality undiscovered gems that might not yet be widely watched but still show solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com